Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Treasury Shares: 2016-2024

Historic Treasury Shares for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $4.1 million.

  • Akebia Therapeutics' Treasury Shares rose 50.60% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year increase of 50.60%. This contributed to the annual value of $4.1 million for FY2024, which is 23.01% up from last year.
  • According to the latest figures from FY2024, Akebia Therapeutics' Treasury Shares is $4.1 million, which was up 23.01% from $3.3 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Treasury Shares registered a high of $5.7 million during FY2022, and its lowest value of $3.3 million during FY2023.
  • For the 3-year period, Akebia Therapeutics' Treasury Shares averaged around $4.4 million, with its median value being $4.1 million (2024).
  • Per our database at Business Quant, Akebia Therapeutics' Treasury Shares increased by 24.59% in 2022 and then tumbled by 41.14% in 2023.
  • Akebia Therapeutics' Treasury Shares (MRY) stood at $4.7 million in 2020, then dropped by 3.62% to $4.6 million in 2021, then increased by 24.59% to $5.7 million in 2022, then plummeted by 41.14% to $3.3 million in 2023, then rose by 23.01% to $4.1 million in 2024.
  • Its Treasury Shares was $4.1 million in FY2024, compared to $3.3 million in FY2023 and $5.7 million in FY2022.